Tuesday, March 10, 2020
The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and mAbxience have obtained the “EXCELLENT” rating in the Profarma Plan 2019, in recognition of their industrial activity and their commitment to development and innovation.
After four consecutive years of obtaining the "Very Good" rating, this plan, an initiative of the Ministry of Industry, Energy and Tourism, grants the highest mark to the Spanish multinational based in Madrid and with a presence in forty countries.
Profarma aims to increase the competitiveness of the pharmaceutical industry in Spain and, to this end, it qualifies participating companies each year based on their excellence in different industrial, economic and research, development and innovation aspects.
In this way, pharmaceutical companies must be able to move towards a change in the production model, so as to increase the ability to attract capital and generate employment, contributing positively to Gross Domestic Product.
Insud Pharma, formerly Grupo Chemo, is a recognized and respected Spanish company in the pharmaceutical and health sector with more than 40 years of history. With nearly 6,000 employees in 40 countries, Insud Pharma makes a huge contribution to global public health, thanks to the medicines and active ingredients it develops and produces through its three synergistic units: industrial (Chemo), brand (Exeltis) and biotechnology (mAbxience).